{
  "metadata": {
    "case_id": 24,
    "model": "Gemini-3-Pro",
    "timestamp": "2025-11-29T15:21:54.127452",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/24_NCT00195091.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Gemini-3-Pro/24_Gemini-3-Pro.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.identificationModule.secondaryIdInfos",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 4,
      "similarity_matrix": [
        [
          0.85,
          0.82,
          0.3,
          0.3
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.85,
          "status": "matched",
          "ref_item": {
            "id": "0309006307",
            "type": "OTHER",
            "domain": "Weill Cornell Medical College"
          },
          "pred_item": {
            "id": "0611008853",
            "type": "OTHER",
            "domain": "Weill Cornell Medicine protocol",
            "link": null
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.9
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "label": "Tetrathiomolybdate (TM)",
            "type": "EXPERIMENTAL",
            "description": "Induction period - TM 40 mg is administered three x per day with meals and TM 60 mg at bedtime for a total of 4 doses (180 mg) per day.\n\nMaintenance Period - Total TM dose per day will be in 20 mg increments to tailor the therapy to individualized patient needs to maintain the Cp level at 5-17mg/dL. Thus all dose modifications will be dependent on individual patient Cp levels. TM 40 mg p.o. BID with meals and TM 20 mg at bedtime. Subjects who have no evidence of disease (NED) and are receiving a benefit of TM can continue taking the drug for up to 120 months.",
            "interventionNames": [
              "Drug: Tetrathiomolybdate"
            ]
          },
          "pred_item": {
            "label": "Tetrathiomolybdate (TM) Treatment Group",
            "type": "EXPERIMENTAL",
            "description": "Patients with breast cancer at high risk for relapse receiving oral copper chelating drug tetrathiomolybdate (TM).",
            "interventionNames": [
              "Drug: Tetrathiomolybdate (TM)"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.97
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.97,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Tetrathiomolybdate",
            "description": "Induction with Tetrathiomolybdate (TM) Tetrathiomolybdate 40 mg. p.o. TID with meals and tetrathiomolybdate 60 mg at bedtime for a total of 4 doses (180 mg) per day.\n\nInduction goal Total tetrathiomolybdate dose per day = 180 mg until serum ceruloplasmin (Cp) level decreases to 5-15mg/dL.\n\nWhen target Cp window is reached, then the maintenance phase begins.\n\nMaintenance with Tetrathiomolybdate Total tetrathiomolybdate dose per day = 100 mg\n\nTetrathiomolybdate 40 mg p.o. BID with meals and tetrathiomolybdate 20 mg at bedtime.",
            "armGroupLabels": [
              "Tetrathiomolybdate (TM)"
            ],
            "otherNames": [
              "TM"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Tetrathiomolybdate (TM)",
            "description": "An oral copper chelating agent administered to deplete copper levels to approximately 30% of baseline.",
            "armGroupLabels": [
              "Tetrathiomolybdate (TM) Treatment Group"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.8,
          0.35
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.8,
          "status": "matched",
          "ref_item": {
            "measure": "Time to Progression for Patients With Breast Cancer Treated With Study Drug",
            "timeFrame": "duration of study"
          },
          "pred_item": {
            "measure": "Event-free survival (EFS)",
            "description": "Defined as the time from study entry to the first documentation of disease progression, new metastatic lesions, or death from any cause.",
            "timeFrame": "Median follow-up of 6.3 years and 9.4 years"
          }
        }
      ]
    }
  ]
}